



Asiatic
Asiatic Laboratories Ltd.
Your Health Partner

Corporate Office

42-43 Siddeshwari Circular Road, Treasure Island (5th Floor)
Shantinagar, Dhaka 1217

Manufacturing Plant

253, Tongi Industrial Area, Tongi, Gazipur-1700, Bangladesh.

Email: investor@asiaticpharma.com

Tel: +880-2-48317908, Fax: +880-2-8311633

PRICE SENSITIVE INFORMATION

This is for kind information of the valued shareholders of Asiatic Laboratories Limited and all concerned that, the Board of Directors of the company in its Board of Directors meeting held on **Wednesday, October 30, 2024 at 5:00pm** at the registered and corporate office **42-43, Siddeshwari Circular Road, Treasure Island (5th Floor), Shantinagar, Dhaka-1217**, Bangladesh took the following Price Sensitive decisions considering the Audited Financial Statements for the year ended **June 30, 2024**:

Sl.	Particulars	Decisions
01.	Recommended Dividend	10% Cash dividend for the year ended 30 June 2024 for all Shareholders excluding Director's and Sponsor. (N.B: The Director's, who shall not be entitled to the recommended Cash Dividend, hold 49,828,490 number of shares out of total 122,393,455 shares. The total amount of Cash Dividend to be payable to the General Shareholders only is Tk.72,564,965.00 for 72,564,965 number of shares.)
02.	Date & Time of the 54 th AGM	Thursday, December 19, 2024 at 11:30am (Bangladesh Local Time).
03.	Platform of the 54 th AGM	Hybrid System (both physical and digital platform)
04.	Venue of the 54 th AGM	Will inform later on
05.	Record Date of the 54 th AGM	Wednesday, November 20, 2024

(Figure in BDT)

Sl.	Particulars	FY (2023-2024)	FY (2022-2023)
01.	Net Profit after Tax	278,476,548	205,847,509
02.	Earnings Per Share (EPS)	2.82	2.19
03.	Net Asset Value (NAV) with Revaluation Surplus	6,435,560,348	5,664,279,770
04.	Net Asset Value (NAV) without Revaluation Surplus	4,811,422,220	4,035,719,195
05.	Net Asset Value Per Share (NAVPS) with Revaluation Surplus	52.58	64.48
06.	Net Asset Value Per Share (NAVPS) without Revaluation Surplus	39.31	45.94
07.	Net Operating Cash Flows Per Share (NOCFPS)	3.15	3.97

Significant deviation in EPS, NAVPS and NOCFPS: EPS has been increased due to increase of the Net Profit after Tax, deferred tax income as well as sales revenue than last year of the Company. NAV with Revaluation Surplus has decreased due to added of IPO fund capitalized and increase of number of ordinary shares, NAV without Revaluation Surplus has been decreased due to added of IPO fund capitalized and increase of number of ordinary shares. NOCFPS has decreased due to the increase of purchase of raw material and operating expenses and payment against said purchase and increase of number of ordinary shares.

Notes:

- Members whose name shall appear in the Depository Register on the 'Record Date' i.e., November 20, 2024 shall be entitled to attend the 54th Annual General Meeting and receive dividend.
- Members are requested to check and update their respective BO ID's, Bank A/C details along with routing number to get dividend online through BEFTN system. Also required to update 12-digit to E-TIN before the record date.

Thanks, and Regards

By Order of the Board of Directors of Asiatic Laboratories Limited

Dated: October 30, 2024

Place: Dhaka

Sd/-

Ishtiaq Ahmed
Company Secretary